Dual GIP and GLP-1 receptor agonist

Tirzepatide

Sold as Mounjaro, Zepbound — once weekly, subcutaneous injection.

Mean weight change · SURMOUNT-1

-20.9%

Placebo arm

-3.1%

Duration

72 wk

What the number means

Mean change in body weight at 72 weeks on the 15 mg dose, treatment-regimen estimand, in adults with obesity or overweight without diabetes.

Trial averages are not a forecast for any individual. Response varies widely, the trial population was screened and supported in ways a subscription is not, and the figure describes people who stayed on the medication for the full period.

Worth knowing

  • The largest average weight change of any approved agent in this class.
  • Gastrointestinal side effects are the most common reason people stop, and are heavily front-loaded into the escalation phase.
  • Supply has been the practical constraint more often than eligibility.

Approved for

Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), including obstructive sleep apnoea in adults with obesity.